Table 2.
Response to Treatment According to Study Group
| Variable | Meglumine Antimoniate (n = 58) | Miltefosine (n = 58) |
| Primary outcome | ||
| Definitive cure at week 26 | 40 | 48 |
| Treatment failure | 16 | 7 |
| Unavailable for follow-up | 1 | 2 |
| Did not complete treatment | 1 | 1 |
| Failure (98% CI), %a | ||
| Per-protocol population | 28.6 (14.5–42.6) | 12.7 (2.3–23.2) |
| Intention-to-treat population | 31 (16.9–45.2) | 17.2 (5.7–28.8) |
Abbreviation: CI, confidence interval.
a
The difference in median failure rates between treatment groups was 15.9 (98% CI, −1.7 to 33.4) for the per-protocol population and 13.8 (−4.5 to 32.0) for the intention-to-treat population.